Professor and Chair
Stanford University
Palo Alto, California, United States
Dr. Michael Lim is a Professor and Chair of Neurosurgery at Stanford University. Dr. Lim obtained his MD from the Johns Hopkins University School of Medicine. He then completed his residency in Neurosurgery at Stanford University Hospital and went on to become a Professor of Neurosurgery, Oncology and Radiation Oncology at Johns Hopkins before returning to Stanford as Chair. Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors and skull base tumors. He has extensive experience in new and innovative neurosurgical techniques including image guided surgery, microsurgery, minimally invasive procedures and endoscopic surgery.
Dr. Lim’s primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors. Findings from his laboratory are directed towards translation to novel therapies against brain tumors. In addition to running a laboratory, he currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory.
Sunday, April 23, 2023
8:50am – 8:52am PST
Disclosure(s): Accuray: Research Grant (Ongoing); Arbor: Research Grant (Ongoing); Biohaven: Consultant (Ongoing), Research Grant (Ongoing); BMS: Consultant (Ongoing), Research Grant (Ongoing); Century Therapeutics: Consultant (Ongoing); CraniUs: Consultant (Ongoing); Egret Therapeutics: Ownership or Partnership (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Hemispherian: Consultant (Ongoing); InCando: Consultant (Ongoing); InCephalo: Consultant (Ongoing), Research Grant (Ongoing); InSightec: Consultant (Ongoing), Research Grant (Ongoing); MediFlix: Consultant (Ongoing); Merck: Consultant (Ongoing); Novocure, Inc.: Consultant (Ongoing), Research Grant (Ongoing); Noxxon: Consultant (Ongoing); Pyarmid Bio: Stock Shareholder (excluding mutual funds) (Ongoing); Sanianoia: Consultant (Ongoing), Grant/Research Support (Ongoing); VBI: Consultant (Ongoing)
(NC5504) Adult and Pediatric Brain Tumor Genomics and Molecular Classifications
Monday, April 24, 2023
7:00am – 3:00pm PST
Disclosure(s): Accuray: Research Grant (Ongoing); Arbor: Research Grant (Ongoing); Biohaven: Consultant (Ongoing), Research Grant (Ongoing); BMS: Consultant (Ongoing), Research Grant (Ongoing); Century Therapeutics: Consultant (Ongoing); CraniUs: Consultant (Ongoing); Egret Therapeutics: Ownership or Partnership (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Hemispherian: Consultant (Ongoing); InCando: Consultant (Ongoing); InCephalo: Consultant (Ongoing), Research Grant (Ongoing); InSightec: Consultant (Ongoing), Research Grant (Ongoing); MediFlix: Consultant (Ongoing); Merck: Consultant (Ongoing); Novocure, Inc.: Consultant (Ongoing), Research Grant (Ongoing); Noxxon: Consultant (Ongoing); Pyarmid Bio: Stock Shareholder (excluding mutual funds) (Ongoing); Sanianoia: Consultant (Ongoing), Grant/Research Support (Ongoing); VBI: Consultant (Ongoing)
(NC5505) Immunotherapy for GBM
Monday, April 24, 2023
12:38pm – 12:52pm PST
Disclosure(s): Accuray: Research Grant (Ongoing); Arbor: Research Grant (Ongoing); Biohaven: Consultant (Ongoing), Research Grant (Ongoing); BMS: Consultant (Ongoing), Research Grant (Ongoing); Century Therapeutics: Consultant (Ongoing); CraniUs: Consultant (Ongoing); Egret Therapeutics: Ownership or Partnership (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Hemispherian: Consultant (Ongoing); InCando: Consultant (Ongoing); InCephalo: Consultant (Ongoing), Research Grant (Ongoing); InSightec: Consultant (Ongoing), Research Grant (Ongoing); MediFlix: Consultant (Ongoing); Merck: Consultant (Ongoing); Novocure, Inc.: Consultant (Ongoing), Research Grant (Ongoing); Noxxon: Consultant (Ongoing); Pyarmid Bio: Stock Shareholder (excluding mutual funds) (Ongoing); Sanianoia: Consultant (Ongoing), Grant/Research Support (Ongoing); VBI: Consultant (Ongoing)